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Abstract: Chlamydia trachomatis is a prevalent sexually transmitted infection that can lead 
to serious reproductive morbidity. Management and control of C. trachomatis is a challenge, 
largely due to its asymptomatic nature and our incomplete understanding of its natural history. 
Although chlamydia screening programs have been implemented worldwide, several countries 
have observed increasing rates of reported chlamydia cases. We reviewed the literature relating 
to the long-term complications of C. trachomatis, as well as screening strategies, treatment, and 
prevention strategies for reducing chlamydia in the population. Articles from 1950–2010 were 
identified through a Medline search using the keyword “Chlamydia trachomatis” combined 
with “screening”, “pelvic inflammatory disease”, “endometritis”, “salpingitis”, “infertility”, 
“ectopic pregnancy”, “urethritis”, “epididymitis”, “proctitis”, “prostatitis”, “reinfection”, 
“  cost-effectiveness”, “treatment”, “vaccines”, or “prevention”. Progression of C.   trachomatis 
  varies, and recurrent infections are common. Currently, there is limited evidence on the 
  effectiveness of chlamydia screening. Higher quality studies are needed to determine the efficacy 
of more frequent screening, on a broader range of sequelae, including infertility and ectopic 
pregnancy, in addition to pelvic inflammatory disease. Studies should focus on delineating 
the natural history of recurrent infections, paying particular attention to treatment failures. 
  Furthermore, alternatives to screening, such as vaccines, should continue to be explored.
Keywords: Chlamydia trachomatis, sexually transmitted disease, chlamydia screening, 
  chlamydia treatment
Introduction
Chlamydia trachomatis genital tract infections are prevalent worldwide and can cause 
serious reproductive morbidity.1 In men, C. trachomatis is associated with   nongonococcal 
urethritis and epididymitis.1–3 In women, chlamydia can lead to   serious complications, 
including pelvic inflammatory disease (PID) and its   subsequent   sequelae, including 
ectopic pregnancy, infertility, and chronic pelvic pain.1,4–6   Chlamydial genital   infections 
have also been reported to increase human   immunodeficiency virus transmission and 
influence the development of human   papilloma virus-induced adenocarcinoma.7,8 
In addition, pregnant women infected with C. trachomatis put their children at risk 
for conjunctivitis and pneumonitis through mother to child transmission.9
The World Health Organization estimates that 92 million new cases of chlamydia 
occur worldwide every year.10 An estimated 3–4 million new cases occur every year in 
the US, 5 million in western Europe, and 16 million in Sub-Saharan Africa.10,11 Among 
men, chlamydia prevalence has been reported to be as high as 15%–20% in high-risk 
populations (such as those attending sexually transmitted disease clinics) and ranges Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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from 3%–7% among asymptomatic populations.1,11,13–16 In 
women, chlamydia prevalence has been reported to range 
from 11.4% to greater than 20% in high-risk populations, 
and among asymptomatic patients has been reported to 
range from 3.0% in the general population to 9.5% among 
university students.1,12,14–19 Due to the burden of chlamydia, 
the US Centers for Disease Control (CDC) recommends 
annual screening for all sexually active women younger than 
26 years.20 Several countries have adopted similar screening 
programs or plan to implement programs that generally focus 
on identification and treatment, screening for asymptomatic 
infection, and partner notification.20–23
In parts of the US and in other countries, there has 
recently been an increase in reported chlamydia cases.20,22–30 
In part, these increasing rates may be attributed to the 
  implementation of new screening practices, reporting of 
chlamydia cases, improvement in diagnostics with increased 
sensitivity, changes in sexual behavior, or changes in natural 
  immunity. One explanation for the rising rates is the “arrested 
  development” hypothesis, where aggressive screening and 
treatment actually blunts natural immunity to chlamydial 
infection, increasing reinfection.26,30 The validity of this 
hypothesis continues to be debated.28–32 Still, the increase 
in reported chlamydia cases has raised concern about the 
effectiveness of current screening programs. This review will 
examine the current management and screening practices, 
as well as the challenges in the control of chlamydia genital 
tract infections.
Methods
Our primary literature search was conducted with Medline 
to identify randomized clinical trials, from 1950 through 
2010, which examined the effectiveness of C. trachomatis 
  screening in reducing reproductive morbidity. The term 
“Chlamydia trachomatis” was combined with “screening”, 
“pelvic inflammatory disease”, “endometritis”, “  salpingitis”, 
“infertility”, or “ectopic pregnancy”. Citations were   limited to 
human studies involving nonpregnant women.   Postabortion 
and transcervical instrumentation studies were excluded. 
This search yielded three randomized clinical   trials examin-
ing the   effectiveness of chlamydia screening to reduce PID 
(see Table). The same key words,   excluding “  screening”, were 
used to identify articles examining   chlamydial complications 
in women. In a separate search, “Chlamydia trachomatis” 
and “reinfection” were   combined with “pelvic   inflammatory 
  disease”, “  endometritis”, “  salpingitis”, “  infertility”, or “  ectopic 
pregnancy”. A new search with keywords “  Chlamydia 
  trachomatis” and “  urethritis”, “  epididymitis”, “proctitis”, 
or “prostatitis” was used to identify articles examining 
  chlamydial   complications in men. Other searches included the 
keywords “  Chlamydia   trachomatis” and “  cost-effectiveness”, 
“treatment”, “  vaccines”, or “  prevention”. We also cross-
referenced articles to identify additional references.
Symptoms, complications, and  
long-term reproductive outcomes
Chlamydial genital tract infections in men
Chlamydial genital tract infections are asymptomatic in 
approximately 50% of men.33,34 If symptoms are present they 
are generally mild,35,36 compromising early identification, 
which may lead to nongonococcal urethritis.1–3,37–39 Urethral 
infection with C. trachomatis can ascend from the lower 
genital tract and cause inflammation of the epididymis, a 
structure on the back of the testicle where sperm is stored, 
a condition known as epididymitis.40–43 Approximately 
45%–85% of men with epididymitis have had prior 
C. trachomatis infections and/or gonococcal infections.40,41,44 
C. trachomatis is also associated with proctitis and inflamma-
tion of the rectal mucosa in both lymphogranuloma venereum 
(LGV , systemic C. trachomatis infection caused by serovars 
L1–L3), and non-LGV strains (genital infection caused by 
serovars B and D–K).1 Once rarely identified in industrialized 
nations, reports of LGV proctitis among men who have sex 
with men have recently been increasing throughout Europe, 
North America, and Australia.45 Because symptoms of LGV 
proctitis are nonspecific and unfamiliar to many physicians 
in industrialized countries, diagnosis may be delayed.45
Chlamydial infections may also cause prostatitis, 
although this relationship has not been completely delineated. 
C. trachomatis has been detected in up to 30% of prostatic 
or semen secretion samples and in 2.2% to 33% of prostate 
tissue samples collected from prostatitis patients.46–56 In 
contrast, a medical record-based retrospective cohort study 
of 17,764 US Air Force males did not find any significant 
associations between C. trachomatis and the development 
of prostatitis (hazard ratio [HR] 1.16, 95% confidence 
interval [CI] 0.82–1.62).57 Furthermore, two studies using 
transperineal biopsy of the prostate, suggested to be the best 
method for reducing contamination from the lower genital 
tract,58 failed to isolate C. trachomatis from any of their 
biopsy patients.58,59 There are several possible reasons for the 
discrepant findings among these studies, including different 
study populations, varying definitions of prostatitis, and 
different C. trachomatis diagnostic methods. Furthermore, 
semen samples, prostatic secretions, and some prostate tissue Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Table Randomized trials examining the effectiveness of screening in preventing pelvic inflammatory disease in nonpregnant women
Author/year Study  
population
Methods Randomization Results
Oakeshott et al92 2529 sexually  
active female  
students, aged  
16–27 years,  
recruited from  
20 universities  
in London, UK.
Participants provided self-collected  
vaginal samples at baseline and  
completed a questionnaire on sexual  
health. CT was diagnosed using TMA.  
After one year, participants completed  
a questionnaire about possible  
symptoms of PID and sexual  
behavior over the past year.  
Medical records were  
collected for 17% and three doctors 
 blinded to study group and  
CT status at baseline allocated  
reported PID cases into  
probable, possible, or no PID,  
using the CDC guidelines and  
Hager’s criteria.
98.6% (2529/2563)  
were randomly  
allocated for  
immediate CT  
screening and  
treatment (1259)  
or deferred screening  
(1186; vaginal samples  
analyzed after one year)  
using random number  
tables. 94% (2377/2529)  
were followed up  
after one year.
Incidence of PID  
was 1.3% (15/1191)  
for screened group and   
1.9% (23/1186) for  
controls (RR 0.65,  
95% CI 0.34–1.22). 
9.5% (7/74) of CT  
positive women at  
baseline in control  
group developed PID.  
1.6% (1/63) of CT  
positive women in  
screening group  
developed PID  
(RR 0.17,  
95% CI 0.03–1.01).
Østergaard et al121 1700 sexually  
active female  
high school  
students from  
Denmark,  
aged $15 years.
Intervention group received a home  
sampling kit at baseline and questionnaire.  
Those who were CT-positive  
(diagnosed by TMA) were referred  
for treatment. The control group  
received the same questionnaire  
with an offer of free testing at a local  
clinic or doctor’s office. Home  
sampling kits were sent at follow-up  
to determine CT incidence.  
Follow-up questionnaire collected  
information on treatment or  
hospitalization for PID during  
the past year. Medical records were  
sought through the central Danish  
register for prescriptions related to PID.
5487 female high  
school students  
were randomized (1:1)  
by simple redeeming  
to a home sampling  
group (2603) or a usual  
care group (2884).  
43% (2351/5487)  
responded to the  
baseline questionnaire.  
Among sexually  
active females 55%  
(930/1700) were  
followed for 1 year.
Incidence of PID  
was 2.1% in  
the intervention  
group and 4.2%  
in the control  
group (P = 0.045).
Scholes et al120 2607 sexually  
active female  
HMO enrollees  
aged 18–34 years  
from Washington  
State, US.
Self-administered questionnaires were  
mailed to single HMO enrollees to  
determine those at high risk of CT  
(based on age, race, gravidity, and  
sexual partner in the past 12 months).  
Emphasis was placed on contacting  
nonresponders who were assigned to  
the screening group. In the screening  
group swabs were tested for CT by  
ELISA. Specimens collected by cytobrush  
were tested by chlamydia cell culture.  
Control group (usual care) saw their  
providers as needed. Both groups  
received a follow-up questionnaire  
at 12 months and were asked about  
diagnosis of PID. Outpatient and  
inpatient databases were used to identify  
those participants with a diagnosis of PID.  
Medical records of those with possible  
cases of PID were reviewed by blinded  
abstracters to determine PID status  
(based on signs, symptoms, and  
laboratory findings).
57% (20,836/36,547)  
responded to the initial  
questionnaire and 85%  
(17,725) of responders  
were ineligible. Of the  
13% eligible (2607),  
1009 were randomly  
assigned (authors did  
not give randomization  
method) to the  
screening group and  
1598 to the  
usual care group. 64%  
(645/1009) of women  
in the screening group  
were tested for CT.  
76% were followed-up  
at 12 months.
Databases identified  
57 participants  
diagnosed with PID.  
Medical records  
showed a clinical  
diagnosis of PID in  
37 participants.  
Additional 5 were  
identified in chart 
review.  
9 confirmed cases  
of incident PID in the  
screening group and  
33 in the usual  
care group (RR 0.44,  
95% CI 0.20–0.90).
Abbreviations: CT, Chlamydia trachomatis; TMA, transcription mediated amplification; PID, pelvic inflammatory disease; CDC, Centers for Disease Control; RR, relative 
risk; CI, confidence interval; HMO, health maintenance organization; ELISA, enzyme-linked immunosorbent assay.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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samples (such as   transrectal biopsy or transurethral resection) 
can be contaminated by the lower genital tract, making it 
  difficult to identify C. trachomatis directly in the prostate.
The debate over the role of C. trachomatis in male upper 
genital tract pathology has also raised questions about the 
impact of chlamydial infection on male fertility. Indeed, 
studies examining the relationship between C. trachomatis 
and male factor infertility have also been inconclusive,57,60–65 
and few high quality prospective studies exist. Still, the 
risk of transmission to female partners leading to PID, 
ectopic pregnancy, or infertility1,4–6 is of great concern. 
  Furthermore, reinfection rates in males have been reported 
to be   approximately 11.3%, which is similar to reinfection 
rates in women.66 Because reinfection in women may be 
  associated with increased risk of reproductive morbidity, 
there is concern over the risk of transmission to female 
partners following repeated infections.
Chlamydial genital tract infections  
in women
Although C. trachomatis generally runs an asymptomatic 
course in approximately 80% of women,34 it is associated 
with serious reproductive morbidity. C. trachomatis can 
infect the columnar epithelial cells of the endocervix and 
cause cervicitis,1,67,68 and is also associated with urethritis.69,70 
Although chlamydial cervicitis is often asymptomatic, it does 
cause mucopurulent discharge in about 37% of women and 
hypertrophic ectopy (an area of ectopy that is edematous 
and bleeds easily) in 19% of women.1 However, there are no 
specific genital symptoms that are correlated with chlamydial 
infection of the cervix for diagnosis.1
Lower genital chlamydial infection can ascend to the 
upper genital tract, leading to serious complications. There 
are several ways C. trachomatis may be able to ascend into 
the upper genital tract. First, C. trachomatis has been shown 
in vitro to be able to attach to spermatozoa,71,72 possibly pro-
moting rapid ascension into the upper genital tract.73 Second, 
the characteristics and production of the mucus plug, which 
is important for the protection against microorganisms, can 
be changed by hormonal fluctuations during the menstrual 
cycle, possibly influencing ascension.74 Hormone levels at 
menarche also increase cervical ectopy in young women,74 
which provides a larger area for bacterial attachment. Lastly, 
subendometrial contractions, which are amplified prior to 
ovulation, may also promote ascension.75
C. trachomatis is a frequent pathogen of PID,76–78 and 
is isolated in the upper genital tract of about a   quarter 
of PID patients.77,79,80 C. trachomatis has been found 
to be   associated with both endometritis81,82 as well as 
  laparoscopically   confirmed salpingitis.77,83–85 However, 
rates of   progression vary widely between patients. Among 
untreated C. trachomatis-positive women, studies have 
reported that 2.0%–4.5% developed clinical PID within 
approximately 14 days.86–88 However, studies with longer 
follow-up have reported lower rates of PID following 
untreated chlamydial infection, ranging from 0%–9.5%.89–92 
In the largest study, conducted in Norway between 1990 
and 2005, 1.09% (48/4413) of women who tested positive 
for C. trachomatis were hospitalized for PID.91 However, 
several methods for chlamydia testing were used through-
out the study period. Furthermore, severe PID resulting in 
hospitalization represents a small proportion of PID cases.74 
Because most cases of PID are mild to moderate and treated 
as outpatients, this study likely represents an underestimation 
of chlamydia-associated PID. In the randomized   controlled 
Prevention Of Pelvic Infection (POPI) trial, 9.5% (7/74) 
of untreated chlamydia-positive women (determined by 
nucleic acid amplification test) developed clinical PID 
within 12 months of follow-up.92 However, only 17% of 
self-reported PID cases were verified by medical records. 
In a prospective study of 1170 women from five US sites, 
19% (23/122) of those with treated chlamydial infection at 
baseline (nucleic acid amplification test) developed clinical 
PID within three years of follow-up.93
Actual rates of progression of chlamydial infection to 
reproductive sequelae are unknown. Studies have found 
associations with prior chlamydial infections and tubal factor 
infertility,94–97 as well as ectopic pregnancy.5,98,99 However, 
very few prospective studies have examined infertility 
  following chlamydial PID. Haggerty et al reported that, among 
a cohort of women with clinically suspected PID, sequelae 
following chlamydial upper genital tract infection was high 
(19.0% infertility, 15.0% recurrent PID, 20.7% chronic pelvic 
pain), although no significant associations were found.80 It is 
possible that women in this cohort could have had prior chla-
mydial infections that resulted in tubal damage preceding the 
PID episode, resulting in bias towards the null. Brunham et al 
found that seven of 13 women with nongonococcal infection 
had an adverse reproductive   outcome, compared with none 
of 10 women with   gonococcal infection (P = 0.007).4 Of the 
seven infertile women, three had evidence of chlamydial 
infection. A retrospective study of 51 women with PID found 
that those who were culture-positive for C. trachomatis were 
more likely to experience involuntary infertility compared 
with those who tested   negative for chlamydia (relative risk 
[RR] 2.5, 95% CI 1.0–6.2).100 Because rates of   progression Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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vary widely between individuals, it is imperative that 
studies strive to understand further the natural history and 
  pathogenesis of C. trachomatis. This will improve treatment 
and control measures, and aid in vaccine development.
Repeated chlamydial infections are common101,102 and 
may increase the risk of sequelae.102–104 In a study of 11,000 
women aged 10–44 years, those who had $three chlamydial 
infections, determined by nucleic acid amplification test, 
were six times more likely to be diagnosed with PID (odds 
ratio [OR] 6.4, 95% CI 2.2–18.4).102 Furthermore, those with 
two infections and $three infections were two times (OR 2.1, 
95% CI 1.3–3.4) and four times (OR 4.5, 95% CI 1.8–5.3) 
more likely to have an ectopic pregnancy.102 Similarly, a 
prospective study among 302 female sex workers in Nairobi, 
Kenya, reported that repeated C. trachomatis infection was 
associated with a cumulative risk of PID over 18 months 
(OR 1.8, 95% CI 1.3–2.4).103 Lastly, Ness et al reported that 
in 443 women with clinically suspected PID, recurrence was 
higher (HR 2.48, 95% CI 1.00–6.27) and pregnancy rates 
were significantly lower (HR 0.47, 95% CI 0.28–0.79) among 
women whose antibody titers to chlamydia elementary bodies 
were in the highest tertile.104
Determining the risk of sequelae following repeated 
  chlamydial infections is difficult because the duration of 
infection is generally unknown. Furthermore, ascertainment 
bias may be present, because physicians who are aware of 
previous infections may be more inclined to diagnose   pelvic 
pain as clinically suspected PID. Still, studies generally 
  suggest that repeated chlamydial infections may increase the 
risk of sequelae. It is important to determine the   epidemiology 
of repeated infections, particularly if they are caused by 
  treatment failures, increased susceptibility to infection due to 
host immunity, or reinfection from an untreated partner.
Screening
Routine screening for C. trachomatis has been implemented 
worldwide, with the goal of interrupting progression or 
  reducing transmission to prevent long-term morbidity. 
  However, there is no single accepted screening strategy that 
has been consistently implemented. Many   screening programs 
target young women under the age of 26 years, focusing on 
identification and treatment, screening for asymptomatic 
infection, and partner notification.20–23 Recommendations 
for screening men varies, but should be evaluated because 
screening both men and women may more adequately reduce 
transmission.22 Frequency of screening also varies between 
programs. The US and the UK often use opportunistic 
screening approaches whereby physicians offer chlamydia 
  screening to young women when they attend health care or 
similar settings for unrelated reasons.105 Retesting is generally 
the responsibility of the physician. Register-based (proactive) 
screening, used in some parts of The Netherlands, utilizes 
a register of the target population and sends invitations for 
screening (invitations are resent to nonresponders) to ensure 
that a high proportion of the target population is reached at 
adequate intervals.105 It is important that countries evaluate 
their screening rates in the population. A high proportion of 
the target population should be reached to ensure that regular 
screening and partner notification are achieved to reduce 
morbidity significantly.
In selected populations, such as sexually active adolescents 
and young women, chlamydia screening is   suggested to be 
cost-effective.106–109 However, there is little evidence that 
chlamydia screening is cost-effective in other populations 
or in males. Furthermore, cost-effectiveness is   suggested 
to be influenced by the rate of complications,110–112 which 
may be lower than previously estimated.111,112 In fact, two 
  studies using a dynamic simulation model reported that 
when   complication rates are low, chlamydia screening may 
not be cost-effective.113,114 These findings suggests that better 
estimates of   morbidity risk are needed to evaluate screening 
  programs   fully.112 However, because the natural history of 
C.   trachomatis has not been completely delineated, estimating 
these risks may be difficult.
Despite screening programs, many countries, such as the 
US, Sweden, and Canada, have recently seen rising rates of 
chlamydia cases.20,22–30 For example, in 2008, 1.2   million 
cases of chlamydia were reported to the US CDC, ie, a 
9.2% increase from 2007 and the largest number of cases 
ever reported to the US CDC for any disease.20 Estimates 
based on case reports need to be interpreted with caution 
because they do not truly reflect prevalence or incidence of 
chlamydial infections. However, C. trachomatis is still very 
much underreported due to its asymptomatic nature, and the 
increased rates may not be artificial.28,30 For example, there 
may be a true increase in incidence, which could ultimately 
lead to an increase in chronic untreated asymptomatic 
  infection, thus leading to a higher prevalence.
There are several possible explanations for the rising 
rates. For example, the switch to more sensitive tests, such 
as nucleic acid amplification testing, introduced in the 
1990s, which can be performed on both urine and female 
self-  collection swabs, may contribute to the increase in 
chlamydial rates. However, Gotz et al report that, in   Sweden 
between 1991 and 1999, increases in chlamydia were reported 
in both laboratories that changed to more sensitive methods Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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and those that did not,28 suggesting that changes in diag-
nostics did not completely account for the increasing rates 
in Sweden.28 Collection by urine or female self-collection 
swabs is an advantage over other testing methods which rely 
on urethral and endocervical swabs. Self-collection swabs 
may be mailed directly from home to a laboratory. Because 
these methods may be more acceptable to people, testing 
rates may have increased as a result. For example, a study 
out of Denmark reported that home-sampling increased the 
number of women tested by 11-fold compared with sampling 
at a doctor’s office.115
There are several other hypotheses that may explain the 
increasing chlamydia rates including changes in sexual behav-
ior, increases in chlamydia reporting, changes in treatment 
failure, failure to achieve adequate partner   notification, and 
changes in natural immunity. In the early 1990s in countries 
without screening programs, reduced chlamydia rates 
coincided with human immunodeficiency virus prevention 
campaigns.105,116 This may suggest that an increase in condom 
use and abstinence could have accounted for the decreasing 
rates, and increases in risky sexual behavior could influence 
rates today. Other hypotheses also exist. The “arrested devel-
opment” hypothesis suggests that aggressive early treatment 
blunts the natural immune response to chlamydial infection, 
essentially increasing the rate of chlamydial reinfection.26,30 
Studies have shown that there is an increase in repeated 
chlamydial infections following treatment.117–119 In addition, 
Brunham et al reported that despite changes in diagnostics 
at different times, C. trachomatis reinfection has increased 
4.6% per year in British Columbia since 1989.26 It is possible 
that women who are screened are in general at higher risk 
for sexually transmitted infections, and thus are more likely 
to have reinfection independent of screening and treatment. 
Still, studies should continue to evaluate the role of host 
immunity in both the course and outcome of chlamydial 
infections, as well as compare immunity, duration, and 
risks of complications in initial and repeated infections. 
If repeated infections truly cause more sequelae than initial 
infections, then more frequent screening or screening focused 
on repeated infections should be evaluated. There is also a 
need for better estimates of chlamydia incidence. Indeed, if 
the observed increases in chlamydia cases do reflect a true 
increase in chlamydia incidence, then current screening 
strategies may not be efficient in reducing transmission.
Low et al argue that the evidence examining the effective-
ness of chlamydia screening is limited, because very few 
randomized clinical trials exist.105 Furthermore, there are no 
randomized trials that have examined complications, such 
as infertility or ectopic pregnancies. One randomized trial 
of 2607 high-risk women recruited from a Seattle health 
maintenance organization found that one-time screening 
significantly reduced the risk of clinical PID (RR 0.44, 95% 
CI 0.20–0.90) within one year of follow-up (see Table).120 
Nonresponders in the intervention group were aggressively 
contacted, which may have resulted in selection bias.120 
In addition, only 64% of the screening group actually 
attended a study clinic for chlamydia testing, and 24% were 
lost to follow-up. In a cluster randomized trial among male 
and female high school students, Østergaard et al reported 
that one-time screening significantly reduced PID (based on 
self-reported treatment and hospitalization for PID) within 
one year when home sampling was compared with usual 
care (4.2% versus 2.1%, P = 0.045).121 The usual care group 
was offered free screening at a local clinic or doctor’s office, 
although only 63 of 833 females in the control group were 
reported to be tested for chlamydia. However, this trial was 
not blinded and approximately 45% were lost to follow-up. 
Furthermore, because chlamydia is not the only cause of PID, 
the estimated effect of screening on PID incidence has been 
suggested to be overestimated in both studies.92,105 In another 
randomized trial (POPI), there was a limited impact of 
annual C. trachomatis screening on self-reported clinically 
suspected PID incidence (RR 0.65, 95% CI 0.34–1.22) 
between women who were screened (1.3%, 15/1191) and 
controls (1.9%, 23/1186).92 However, the incidence of PID 
was only 1.9%, which was lower than the estimated 3% used 
to power the study.
When evaluating the effectiveness of screening programs 
to reduce reproductive morbidity, there are several possible 
limitations in using PID as an outcome. First, several other 
microorganisms have been implicated in the etiology of PID, 
making it difficult to determine the proportion of PID cases 
specifically attributed to C. trachomatis. Second, signs and 
symptoms of PID vary widely, thus diagnosis of clinically 
suspected PID is nonspecific. Lastly, C. trachomatis has 
been found to increase the odds of subclinical PID six-fold 
(OR 6.1, 95% CI 1.8–2.1),122 suggesting that increases in 
C. trachomatis upper genital tract infection may increase 
subclinical PID in the population. Women with subclinical 
PID have very mild or no symptoms,74 and PID may go 
undiagnosed in many women with chlamydial infection. 
Thus, the effectiveness of screening programs to reduce 
other reproductive sequelae should be explored. However, 
infertility can also be difficult to diagnose, because it can 
take years to develop and has several different causes. In 
addition, infertility can only be measured in women actively Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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trying to conceive or those who rarely or never use reliable 
contraceptive methods. This same issue applies to ectopic 
pregnancy. Therefore, improved diagnostic methods for 
postchlamydial complications with high sensitivity and 
specificity are needed.
Treatment and prevention
Treatment of C. trachomatis infection is considered to be 
effective in preventing transmission to sexual partners.123 
Several drugs are active against C. trachomatis in tissue 
cultures, including rifampin, tetracyclines, macrolides, 
sulfonamides, some fluoroquinolones, and clindamycin.1 
Rifampin is highly active in vitro, but resistance to this 
drug can be readily developed.124 Thus, rifampin is not used 
to treat human chlamydial infections.1 C. trachomatis is 
also susceptible to sulfonamides, but they are not used for 
genital chlamydial infections.125 Currently, the US CDC 
recommends treatment with azithromycin (1 g, single dose 
taken orally) or doxycycline (100 mg, twice per day for 
seven days).123 A recent meta-analysis revealed similar micro-
biological cure rates for azithromycin (97%) and doxycycline 
(98%).126 Azithromycin is recommended when compliance 
may be an issue, such as in adolescents or those with low 
socioeconomic status due to its ability to be given in a single 
dose. Alternative regimens can include erythromycin base 
(500 mg four times per day for seven days), erythromycin 
ethylsuccinate (800 mg four times per day for seven days), 
ofloxacin (300 mg twice a day for seven days), or levofloxa-
cin (500 mg daily for seven days).123 Erythromycin is effec-
tive in treating chlamydia, but has side effects, which may 
reduce compliance.123 Levofloxacin and ofloxacin are also 
effective, but are expensive.123 There is currently no solid evi-
dence of any in vivo antibiotic resistance for C. trachomatis 
genital tract infection.1,30,125 However, very few laboratories 
actually monitor chlamydial antibiotic resistance.30 Although 
recurrent infections are common in both men and women, it 
is unclear if they are due to treatment failures. In the US, it 
is likely that many treatment failures go unnoticed in asymp-
tomatic infection, because test-of-cure (repeat testing three 
to four weeks after completing therapy) is not recommended, 
except in pregnant women.123
Vaccines
The asymptomatic nature of chlamydia makes diagnosis, 
treatment, and prevention of sequelae a challenge. Host 
immunity induced by chlamydial infections is not long-
lasting, and may take several months or years to develop.125 
Further, a single C. trachomatis infection does not adequately 
  protect against reinfection.125 In addition, it is hypothesized 
that aggressive treatment may blunt natural immunity.26,30 
  Therefore, control and management of chlamydia may 
depend on a safe and effective vaccine that can induce a   better 
immune response than what occurs naturally.125 However, 
the pathogenesis of C. trachomatis has not been completely 
elucidated, and the role of host immunology is unclear. 
Coupled with a lack of a suitable animal model and inability 
to manipulate chlamydia genetically, researchers have yet to 
develop a successful vaccine.
Chlamydial surface antigens are possible vaccine 
candidates.125 Several chlamydial vaccine trials have used 
the major outer membrane protein as a vaccine candidate. 
However, studies using the major outer membrane protein 
have been inconclusive and immunity is generally short-
lived.127–131 Furthermore, the major outer membrane protein 
is not serovar-specific. Thus, other antigens are currently 
being considered as vaccine candidates. The recently dis-
covered surface-exposed protein, polymorphic membrane 
protein D, has been shown to act as an adhesion molecule132 
and can stimulate proinflammatory cytokines through 
the nuclear factor-kB pathway.133 Crane et al found that 
  polymorphic membrane protein can recruit host antibodies to 
the site of infection, making this protein a promising   vaccine 
  candidate.134 Antibody response was also neutralizing across 
different serovars. However, chlamydia may undergo a type 
of antigenic variation.135 Thus, it has been suggested that a 
single antigen may not be optimal as a vaccine candidate. 
Further increasing our knowledge of chlamydial pathogen-
esis will bring researchers closer to developing a successful 
vaccine.
Conclusion
There are several factors which may hinder the implementa-
tion of a successful chlamydia screening program. First, the 
evidence examining the effectiveness of chlamydia   screening 
is limited, because few high quality randomized clinical 
  trials exist. Furthermore, chlamydia screening   strategies 
vary widely, and there is no evidence to suggest which 
screening strategy would best reduce reproductive morbidity. 
  Second, cost-effective analyses, which are mainly conducted 
in young women, may be inaccurate because complication 
risks are lower than previously estimated. In fact, two studies 
using dynamic simulation models have suggested that chla-
mydia screening is not cost-effective when based on lower 
complication rates. Lastly, the high rate of repeated infections 
in the population and our incomplete understanding of the 
natural history of C. trachomatis have greatly challenged Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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control efforts. Because the natural history of C. trachomatis 
has not been completely elucidated, it is unclear if screening 
can successfully interrupt progression before tubal damage 
and/or reduce transmission in the population.
It is clear that future research is needed to determine the 
best approach for chlamydia management. While it is dif-
ficult to assess screening programs, it would be optimal if 
the efficacy of more frequent C. trachomatis screening on a 
broader range of sequelae were explored, including infertility 
and ectopic pregnancy in addition to PID. Due to the 
previously mentioned limitations of using these outcomes to 
evaluate screening programs, improved   diagnostic   methods 
for chlamydial complications are needed.   Alternatively, 
better estimates of chlamydia incidence can be used to 
determine if screening can efficiently reduce   transmission. 
Because studies evaluating chlamydia screening have 
largely been conducted in women, future investigations 
should also focus on men. This is of particular importance 
because C. trachomatis is asymptomatic in half of men, 
leaving a high likelihood of transmission to sexual partners. 
It is imperative that the   natural history and epidemiology of 
C. trachomatis continues to be explored in both single and 
repeated infections. Research should continue to explore 
host immunology, bacterial antigens, duration, and the role 
of pathogen load in the course and outcome of chlamydial 
infections. In addition, it is particularly important that future 
studies determine if repeated infections are caused by treat-
ment failure. As chlamydia research progresses, current 
screening programs need to be evaluated carefully and other 
alternatives to screening, such as vaccine development, 
should continue to be explored.
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